Hepatosplenic T-cell lymphoma
MONDO:0019474An extranodal, mature T-cell non-Hodgkin lymphoma that originates from cytotoxic T-cells, usually of gamma/delta T-cell type. It is characterized by the presence of medium-size neoplastic lymphocytes infiltrating the hepatic sinusoids. A similar infiltrating pattern is also present in the spleen and bone marrow that are usually involved at the time of the diagnosis.
Also known as: Hepatosplenic gamma/Delta T-cell lymphoma, HSTCL
1943 clinical trials for this condition and its sub-types, 16 tagged with Hepatosplenic T-cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a powerful combo of drugs and stem cell transplant beat tough lymphomas in kids?
Cure Recruiting nowThis trial is testing a two-step approach for children, teens, and young adults with advanced T-cell or NK-cell lymphoma or leukemia. First, patients receive a combination of chemotherapy and immunotherapy drugs to shrink the cancer. Then, those who respond go on to receive a ste…
Early phase 1 • Sponsor: New York Medical College • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Gene therapy trial targets tough T-Cell cancers
Disease control Recruiting nowThis early-stage trial tests a new gene therapy for certain T-cell lymphomas that have come back or not responded to treatment. The therapy uses a patient's own white blood cells, modified to attack cancer cells that carry a protein called CCR4. Up to 60 adults will receive the m…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New hope for rare blood cancer: Two-Drug combo trial launches
Disease control Recruiting nowThis phase 3 trial tests whether adding either belinostat or pralatrexate to standard chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…
Phase 3 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for rare blood cancers: first human trial launches
Disease control Recruiting nowThis study tests a new drug called DR-01 in adults with rare types of leukemia or lymphoma. The goal is to see if it is safe and can shrink tumors. About 200 people will take part in this early-stage trial.
Phase 1/2 • Sponsor: Dren Bio • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo shows promise for rare lymphoma in Real-World study
Disease control Recruiting nowThis observational study tracks 100 adults in Spain with CD30-positive peripheral T-cell lymphoma who received brentuximab vedotin plus CHP as their first treatment. Researchers will review medical records to see how long patients live without their cancer getting worse, how well…
Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Massive T-Cell lymphoma database aims to unlock new insights
Knowledge-focused Recruiting nowThis study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC